Ian Mortimer $XENE SEC Form 4 Insider Trading

Ian Mortimer has filed a total of 26 insider trades in $XENE since 2021. Their most recent trade was a purchase of 30,000 shares, made on Sep 30, 2026. Their largest trade was a sale of 65,000 shares, made on Mar 09, 2026. We estimate that they now own 125,000 shares of $XENE, worth an estimated $739,740.

Insider Trading at $XENE

There have been a total of 106 insider trades reported at $XENE since 2021, with 49,700 shares purchased and 1.2 million shares sold. The most active insider traders in $XENE stock have been Ian Mortimer, Sherrington Robin, and Christopher John Kenney. The most recent trade was a purchase of 15,000 shares reported by Thomas Patrick Kelly (Chief Financial Officer), made on Sep 30, 2026.

$XENE Executives and Stock Owners with Insider Trades

• Ian Mortimer, PRESIDENT & CEO

• Sherrington Robin, EVP, Strategy & Innovation

• Christopher John Kenney, Chief Medical Officer

• James R. Empfield, EVP, Drug Discovery

• Sherry Aulin, Chief Financial Officer

• Andrea Difabio, Chief Legal Officer

• Ian Mortimer, PRESIDENT, CEO & INTERIM CFO

• Seggern Christopher Von, Chief Commercial Officer

• Thomas Patrick Kelly, Chief Financial Officer

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.